Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Stop comparing SZLS to EXAS
View:
Post by Stockish12 on Mar 22, 2021 1:13pm

Stop comparing SZLS to EXAS

This is how you know most of these guys that just spew prices and projections on here are just plain dumb or wishful gamblers.

Its simple. I do not care if SZLS claims to have a product that can test 10 cancers. The 2 companies are not comparable.

1. Management team: Read up about the Management team of EXAS. It is like day and light when compared with SZLS. Tripp cannot raise 1/10 of what those guys raised in the market. He lacks the technical know how.

2. EXAS's cologuard had its first fda approval in 2014. Aristotle has none and there is nothing in the works towards that. For a product like this to hit the main market, FDA approval is key.

Always do DD and think before posting senseless SPs. At best, this product will hit a few local laboratories. Price may double or triple from here at the most and then fall. Oh wait, thats if the Q1 release is real.
Comment by gojotv! on Mar 22, 2021 1:45pm
True. There is no comparison. Aristotle is far more comprehensive a test and will initially be available in StageZero labs. You can do tests in-house without FDA approval. They are going to be swamped with demand. Which is great, because it's a better way to manage growth. You can't go from 0 to 10 without going through 2,3,4,5,6,... That's the way to make costly mistakes in business ...more  
Comment by Eoganacht on Mar 22, 2021 3:03pm
No one said a $100 sp would come overnight. SZLS is flush with covid test cash and FDA trials will come in due course. Aristotle will launch some time in the next 7 working days, and it's impact will go far beyond a few local laboratories. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities